These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 12966674)

  • 1. Cancer patients with bone complications prefer infusion of zoledronic acid.
    Oncology (Williston Park); 2003 Aug; 17(8):1070. PubMed ID: 12966674
    [No Abstract]   [Full Text] [Related]  

  • 2. "Safety and convenience of a 15-minute infusion of zoledronic acid": not so safe.
    Lugassy G
    Oncologist; 2005 May; 10(5):309-10; author reply 311-2. PubMed ID: 15851782
    [No Abstract]   [Full Text] [Related]  

  • 3. Regarding "recommendations for zoledronic acid treatment of patients with bone metastases".
    Parles K
    Oncologist; 2005 May; 10(5):304-5. PubMed ID: 15851780
    [No Abstract]   [Full Text] [Related]  

  • 4. The issue of renal safety of zoledronic acid from a nephrologist's point of view.
    Balla J
    Oncologist; 2005 May; 10(5):306-8; author reply 311-2. PubMed ID: 15851781
    [No Abstract]   [Full Text] [Related]  

  • 5. Denosumab and bone metastases. No better than a bisphosphonate.
    Prescrire Int; 2012 Sep; 21(130):204-6. PubMed ID: 23016249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate infusions: patient preference, safety and clinic use.
    Chern B; Joseph D; Joshua D; Pittman K; Richardson G; Schou M; Lowe S; Copeman M; De Abreu Lourenco R; Lynch K
    Support Care Cancer; 2004 Jun; 12(6):463-6. PubMed ID: 15088136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi study.
    Xie F; Hopkins R; Burke N; Tarride JE; Goeree R
    Hosp Pract (1995); 2012 Apr; 40(2):131-7. PubMed ID: 22615087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.
    Wardley A; Davidson N; Barrett-Lee P; Hong A; Mansi J; Dodwell D; Murphy R; Mason T; Cameron D
    Br J Cancer; 2005 May; 92(10):1869-76. PubMed ID: 15870721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid.
    Maxwell C; Swift R; Goode M; Doane L; Rogers M
    Clin J Oncol Nurs; 2003; 7(4):403-8. PubMed ID: 12929273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
    Gordon DH
    Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations for zoledronic acid treatment of patients with bone metastases.
    Berenson JR
    Oncologist; 2005 Jan; 10(1):52-62. PubMed ID: 15632252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates and metastatic breast carcinoma.
    Lipton A
    Cancer; 2003 Feb; 97(3 Suppl):848-53. PubMed ID: 12548585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid is effective in the treatment of prostate cancer patients with bone metastases.
    Maung K
    Clin Prostate Cancer; 2002 Jun; 1(1):12-3. PubMed ID: 15046707
    [No Abstract]   [Full Text] [Related]  

  • 15. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
    Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and convenience of a 15-minute infusion of zoledronic acid.
    Berenson J; Hirschberg R
    Oncologist; 2004; 9(3):319-29. PubMed ID: 15169987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Berenson J, Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid.
    Diel IJ; Bergner R
    Oncologist; 2005 Jan; 10(1):82-3; author reply 84-7. PubMed ID: 15632256
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute Bilateral Anterior Uveitis after a Single Intravenous Infusion of Zoledronic Acid in Metastatic Breast Cancer.
    Jun JH
    Korean J Ophthalmol; 2017 Aug; 31(4):368-369. PubMed ID: 28682020
    [No Abstract]   [Full Text] [Related]  

  • 19. Zoledronic acid (Zometa): bisphosphonate for prostate cancer/bone metastases.
    Gaines KK
    Urol Nurs; 2002 Dec; 22(6):398-400. PubMed ID: 12593231
    [No Abstract]   [Full Text] [Related]  

  • 20. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
    Barrett-Lee P; Casbard A; Abraham J; Hood K; Coleman R; Simmonds P; Timmins H; Wheatley D; Grieve R; Griffiths G; Murray N
    Lancet Oncol; 2014 Jan; 15(1):114-22. PubMed ID: 24332514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.